R&G PharmaStudies Co., Ltd.

SZSE:301333 Stock Report

Market Cap: CN¥5.7b

R&G PharmaStudies Future Growth

Future criteria checks 4/6

R&G PharmaStudies is forecast to grow earnings and revenue by 27% and 18.1% per annum respectively. EPS is expected to grow by 22.8% per annum. Return on equity is forecast to be 10.3% in 3 years.

Key information

27.0%

Earnings growth rate

22.8%

EPS growth rate

Life Sciences earnings growth31.9%
Revenue growth rate18.1%
Future return on equity10.3%
Analyst coverage

Low

Last updated19 Nov 2024

Recent future growth updates

Recent updates

R&G PharmaStudies' (SZSE:301333) Conservative Accounting Might Explain Soft Earnings

Nov 06
R&G PharmaStudies' (SZSE:301333) Conservative Accounting Might Explain Soft Earnings

R&G PharmaStudies' (SZSE:301333) Dividend Will Be Reduced To CN¥0.20

Jul 01
R&G PharmaStudies' (SZSE:301333) Dividend Will Be Reduced To CN¥0.20

Is There An Opportunity With R&G PharmaStudies Co., Ltd.'s (SZSE:301333) 27% Undervaluation?

Jun 06
Is There An Opportunity With R&G PharmaStudies Co., Ltd.'s (SZSE:301333) 27% Undervaluation?

Shareholders Will Be Pleased With The Quality of R&G PharmaStudies' (SZSE:301333) Earnings

Apr 29
Shareholders Will Be Pleased With The Quality of R&G PharmaStudies' (SZSE:301333) Earnings

Earnings and Revenue Growth Forecasts

SZSE:301333 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,130234N/A2412
12/31/2025982205N/A2104
12/31/2024811162N/A1483
9/30/2024759121152169N/A
6/30/2024738135194211N/A
3/31/2024738157177198N/A
12/31/2023721163173193N/A
9/30/2023694155175197N/A
6/30/2023673138106128N/A
3/31/2023628115126144N/A
1/1/2023638113110130N/A
9/30/2022634112121154N/A
6/30/202264011093127N/A
3/31/202263210166102N/A
1/1/20226089976115N/A
12/31/2020484841944N/A
12/31/20194258377103N/A
12/31/201514224N/A17N/A
12/31/20149614N/A24N/A
12/31/20137812N/A10N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 301333's forecast earnings growth (27% per year) is above the savings rate (2.8%).

Earnings vs Market: 301333's earnings (27% per year) are forecast to grow faster than the CN market (26.3% per year).

High Growth Earnings: 301333's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 301333's revenue (18.1% per year) is forecast to grow faster than the CN market (13.9% per year).

High Growth Revenue: 301333's revenue (18.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 301333's Return on Equity is forecast to be low in 3 years time (10.3%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y